Mum | Jotup

Many Australians face losing their homes right now. Here’s how the government should help

Retrieved on:

火曜日, 4月 23, 2024

That same principle underpins the HomeKeeper program I proposed in The Conversation last year.

Key Points:

That same principle underpins the HomeKeeper program I proposed in The Conversation last year.
The idea is to help mortgage-stressed owner-occupiers avoid losing their home.
If it’s a good idea for companies, why not for responsible and otherwise financially-viable Australians at risk of losing their homes in a cost-of-living crisis?
Rather, it’s government help through a small equity stake with positive returns for taxpayers when HomeKeeper help is no longer needed.

People need help now

HomeKeeper would be of most help to lower income families who often don’t have a “Bank of Mum and Dad” to help them “over the hump”, as Albanese puts it, during temporary difficulties.
ACT Independent Senator David Pocock backed HomeKeeper last week in his additional comments in the Senate Economics Legislation Committee report on the government’s Help To Buy Bill 2023.
Pocock wants the government’s Help To Buy mechanism amended to enable low- and middle-income earners “facing mortgage repossession and possible homelessness to remain in home ownership” via a HomeKeeper-style program.
Establishing HomeKeeper is more important than ever because the monetary policy script isn’t following the arc politicians and policymakers planned.

Relying on interest rate relief to arrive isn’t enough

Yet interest rates in Australia are not falling.
What’s more, even without further rate increases by the Reserve Bank of Australia (RBA) this year, the average mortgage rate is set to rise anyway according to research by the RBA’s Domestic Markets Department’s Benjamin Ung.
Nearly a third (31.4%) of mortgaged owner-occupiers are “at risk” of mortgage stress according to the latest Roy Morgan survey.
The longer it takes, the more damaging to individuals and families, and the more costly it is to governments.
Albanese is right – sometimes there’s a role for government in providing help to get over that hump.

Chris Wallace is a professor in the University of Canberra's School of Politics Economics & Society, Faculty of Business Government & Law. She has received funding from the Australian Research Council.

Hatch Introduces Personalized Feature Bringing Bedtime to Those Who Can't Be There

Retrieved on:

木曜日, 4月 4, 2024

Mindfulness, Friends, Entrepreneurship, Mum, Hearing, Journal, Sleep, Child, Behavior, PALO, The Journal of Pediatrics, Family, Parent, Human, Toy

PALO ALTO, Calif., April 4, 2024 /PRNewswire/ -- Hatch, a sleep wellness company that teaches the whole family better sleep habits, is launching a new premium feature for its baby and kids' Rest devices that can bring family and friends closer together, no matter the distance.

Key Points:

"We know that raising a child takes a village, and when that village isn't physically present it can feel isolating," says Ann Crady Weiss, Co-Founder and CEO of Hatch.
"Tuck-Ins can create a meaningful, sleep-inducing bedtime routine for your little one.
As we celebrate our 10-year anniversary, we are excited to expand our unique feature and premium Hatch+ content offerings to benefit the whole family, and we believe Tuck-Ins is a prime example of this."
"Tuck-Ins by You has become a bedtime special - it's like Mum is really there reading to my kids!"

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on:

水曜日, 2月 28, 2024

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points:

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Retrieved on:

木曜日, 2月 22, 2024

Mum, Liver, Caregiver, Physician, Delcath Systems, Uveal melanoma, Lung, Locator, Radiation, Lymph, Health care, Patient

NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website.

Key Points:

NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website.
Potential patients, caregivers, and healthcare providers may use the Locator to identify healthcare settings, offering treatment with the HEPZATO KIT.
Sites included on the Locator are accepting inquiries from patients or their physicians seeking potential treatment with HEPZATO KIT.
"The Healthcare Settings Locator is a great resource for metastatic uveal melanoma patients.

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Retrieved on:

水曜日, 1月 31, 2024

Multiple myeloma, Delcath Systems, Lymph, Patient, Mum, FDA, Lung, Radiation, CMS, Liver, Medicare, Hospital

The J-code will become effective on April 1, 2024.

Key Points:

The J-code will become effective on April 1, 2024.
J-codes are a form of Healthcare Common Procedure Coding System Level II identifiers used by payors to streamline the billing of Medicare Part B drugs.
"We believe that the establishment of the permanent J-code for HEPZATO will facilitate patient access to this important treatment," said Gerard Michel, Delcath's Chief Executive Officer.
"This is a significant step towards accurate and efficient reimbursement of the HEPZATO KIT, facilitating access for patients."

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™

Retrieved on:

火曜日, 1月 16, 2024

Senior, Region, Patient, Lead, Delcath Systems, FOCUS, Liver, Mum, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma (mUM).

Key Points:

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma (mUM).
"The fact that patients with difficult to treat metastatic uveal melanoma with limited treatment options now have another alternative is truly remarkable and exciting.
In conjunction with the first commercial treatment, Delcath also launched websites relating to the HEPZATO KIT, including HEPZATO KIT , HEPZATO KIT REMS , and HEPZATO KIT Access , to support the commercial launch.
"The first commercial procedure utilizing HEPZATO KIT in the U.S. is a significant milestone for Delcath and patients suffering from metastatic uveal melanoma.

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma

Retrieved on:

月曜日, 11月 13, 2023

Uveal melanoma, Disease, Mum, OTCQB, Liver, Mortality, Patient, CMR, Kaplan–Meier estimator, Nivolumab, Ipilimumab, PET-CT, Springfield Armory M1A, Acceptability, Renewable energy, Pharmaceutical industry, Medical imaging

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).

Key Points:

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).
mUM patients enrolled in this study received 1 or more cycles of PV-10 injection into 1 or more hepatic metastases.
Where indicated, standard of care immune checkpoint blockade (CB), as either monotherapy pembrolizumab or the combination of ipilimumab and nivolumab (IN), was also administered.
Dominic Rodrigues, Vice Chair of the Provectus’s Board of Directors, said, “Objective response is uncommon and complete metabolic response is rare in metastatic uveal melanoma.

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Retrieved on:

土曜日, 10月 21, 2023

“These long-term overall survival results further solidify KIMMTRAK as the first-line standard of care for HLA-A*02:01 positive patients with metastatic uveal melanoma,” said Mohammed Dar, Immunocore Chief Medical Officer.

Key Points:

“These long-term overall survival results further solidify KIMMTRAK as the first-line standard of care for HLA-A*02:01 positive patients with metastatic uveal melanoma,” said Mohammed Dar, Immunocore Chief Medical Officer.
Overall response rate remained in favor of KIMMTRAK when compared with the control arm (11% vs 5%) and the median duration of response for KIMMTRAK patients was 11.1 months.
The trial evaluated circulating tumor DNA (ctDNA) clearance as a predictor of overall survival.
Session: Mini oral session – Melanoma and other skin tumours, Saturday 21 October, 2023
Title: Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase 3 randomized trial of tebentafusp in first line metastatic uveal melanoma: long-term follow up

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Retrieved on:

金曜日, 10月 13, 2023

Gene expression, Treatment, ESMO, University, Mum, MD Anderson Cancer Center, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the dose escalation and expansion study of FHD-286 in metastatic uveal melanoma (mUM) will be presented at the ESMO Congress 2023, to be held October 20–24 in Madrid, Spain.

Key Points:

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the dose escalation and expansion study of FHD-286 in metastatic uveal melanoma (mUM) will be presented at the ESMO Congress 2023, to be held October 20–24 in Madrid, Spain.
Title: A Phase 1 Dose Escalation and Expansion Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, for the Treatment of Metastatic Uveal Melanoma
Presenter: Dr. Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Retrieved on:

水曜日, 10月 4, 2023

Synovial sarcoma, AACR, UM, CBP, DLBCL, Foghorn, NGS, Chromatin, BRM, BRG1, Mum, Gene expression, NSCLC, Prostate, Biomarker, Lung cancer, EP300, Acute myeloid leukemia, B cell, MDS, Malignancy, AML, BAF, Patient, Lymphoma, Neoplasm, BRD9, AR, Conference, Prostate cancer, Pharmaceutical industry, Vaccine, Science

The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Key Points:

The conference will be held October 11–15, 2023, in Boston, Massachusetts.
Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.
Also at AACR-NCI-EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines.
The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.